News - Anormed Inc.
CAMBRIDGE, Mass., Jan. 9 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that revenue increased 17 percent in the fourth quarter of 2006 to $852 million, up from $729 million in the fourth quarter a year earlier.
By Stephen Heuser, The Boston Globe Oct. 11--The unusual bidding war between two of the marquee names in Cambridge biotechnology, Genzyme Corp. and Millennium Pharmaceuticals Inc.
By Stephen Heuser, The Boston Globe Sep. 27--In a surprise attempt by a Cambridge biotechnology company to trump a takeover bid by one of its neighbors, Millennium Pharmaceuticals Inc. yesterday said it had reached a $515 million deal to buy a small Canadian drug firm that Genzyme Corp.
CAMBRIDGE, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced it has entered into an agreement to acquire AnorMED, Inc. (Nasdaq: ANOR; TSX: AOM), a Canadian-based biopharmaceutical company with a late-stage Phase III hematology-oncology product, MOZOBIL.